Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
The MDS 2026 congress will feature industry-sponsored sessions, satellite symposia, and poster presentations showcasing pharmaceutical company pipelines for movement disorders. This page tracks the expected industry presentations and drug development programs.
| Drug/Program |
Company |
Mechanism |
Stage |
| α-Synuclein Antibodies |
Various |
Immunotherapy |
Phase 2/3 |
| LRRK2 Inhibitors |
Denali, Biogen |
Kinase inhibition |
Phase 2 |
| GBA Gene Therapy |
Prevail/Eli Lilly |
Gene replacement |
Phase 1/2 |
| GLP-1 Receptor Agonists |
Novo Nordisk, others |
Neuroprotection |
Phase 3 |
- Extended-Release Formulations: Novel delivery systems
- Continuous Infusion Therapies: Levodopa-carbidopa intestinal gel
- Adenosine A2A Antagonists: Istradefylline approved, follow-ons in development
- Gene Therapy: AAV-based approaches (AAV2-GAD, AADC)
- Cell Therapy: Stem cell-derived dopamine neurons
- Deep Brain Stimulation: Directional leads, closed-loop systems
| Drug/Program |
Company |
Mechanism |
Stage |
| ASOs |
Roche, Wave Life Sciences |
HTT mRNA silencing |
Phase 1/2 |
| CRISPR/Cas9 |
Various |
Gene editing |
Preclinical |
| RNA Editing |
Various |
A-to-I editing |
Preclinical |
- Molecular Chaperones: Protein aggregation inhibitors
- Neuroprotective Agents: Mitochondrial protectors
- Anti-inflammatory Therapies: Microglial modulation
- CoQ10 and Analogues: For Friedreich's ataxia and mitochondrial disorders
- Antisense Oligonucleotides: SCA1, SCA3 programs
- Gene Therapy: AAV-based frataxin delivery
- DBS Devices: New-generation directional leads
- Botulinum Toxin: New formulations
- Small Molecules: Novel muscle relaxants
Major pharmaceutical companies typically host satellite symposia covering:
- Clinical trial results
- Pipeline updates
- Expert panels on treatment strategies
Industry and academic researchers present:
- Phase 1/2 trial results
- Preclinical data
- Real-world evidence studies
- Company booths with product information
- Clinical trial recruitment
- Medical affairs discussions
- AbbVie — Parkinson's disease, dystonia
- Biogen — LRRK2 inhibitors, Alzheimer's
- Boehringer Ingelheim — Parkinson's disease
- Bristol Myers Squibb — Parkinson's disease
- Denali Therapeutics — LRRK2, GBA, TNF
- Eli Lilly/Prevail — Gene therapy
- ** Ipsen** — Botulinum toxins
- Merck — Parkinson's disease
- Novartis — Parkinson's disease, SMA
- Novo Nordisk — GLP-1, neurodegeneration
- Roche — Huntington's disease
- Takeda — Rare movement disorders
- UCB — Epilepsy, movement disorders
- Biomarker-Driven Trials: Using biomarkers for patient selection
- Adaptive Designs: Platform trials, master protocols
- Disease Progression Models: Long-term outcome prediction
- Digital Endpoints: Wearable devices, digital biomarkers